PTH Analogs: Mechanism, Uses, and Side Effects

PTH analogs are synthetic versions of parathyroid hormone, a molecule your body naturally produces to regulate calcium and maintain bone. These drugs exploit a quirk of biology: while constant exposure to PTH breaks bone down, brief daily pulses of it stimulate new bone formation. That distinction between continuous and intermittent exposure is the foundation of an entire class of osteoporosis treatments and, more recently, therapies for people whose parathyroid glands don’t produce enough hormone on their own. The science behind these drugs, the conditions they treat, and the risks they carry are worth understanding in detail, especially because the field has shifted considerably in the last few years.

How Brief Pulses Build Bone

Parathyroid hormone acts on the same cells whether you get a short burst or a long soak, but the downstream effects diverge sharply. Intermittent, low-dose PTH favors bone building, while continuous exposure tilts the balance toward bone loss. This has been understood since at least the early 1990s, when animal studies showed that rats given the same total daily dose of PTH gained bone mass if it was delivered as an injection but lost bone mass if it was infused continuously.¹ In humans, chronic overproduction of PTH (as happens in hyperparathyroidism) causes a damaging condition called osteitis fibrosa, marked by softened bone, focal erosion, and scarring of the marrow.²

The reason for this split comes down to which bone cells respond first. A short spike of PTH predominantly activates osteoblasts, the cells that deposit new bone matrix. It also suppresses sclerostin, a protein made by osteocytes (the mature cells embedded in bone) that normally puts the brakes on bone formation. One of the key molecular switches involves an enzyme called SIK2 inside osteocytes: when PTH hits the cell, it inhibits SIK2, which in turn reduces sclerostin levels and allows bone-building signals to proceed.³ But PTH also activates osteoclasts, the cells that dissolve bone, through a separate signaling arm. When the hormone is present only briefly, the bone-building arm gets a head start. When it’s present all day, osteoclast activity catches up and overtakes the formation side.

The Drugs on the Market

Three PTH-based drugs are currently approved in the United States, each designed for somewhat different situations.

Teriparatide: A synthetic copy of the first 34 amino acids of human PTH, sold as Forteo. It’s given as a daily subcutaneous injection and was the first bone-building drug approved for osteoporosis, reaching the market in 2002.
Abaloparatide: A synthetic analog of PTH-related protein (PTHrP), sold as Tymlos. It binds the same receptor as teriparatide but in a slightly different configuration, which may account for some differences in how it affects calcium levels and bone density at different skeletal sites. Also a daily injection.
Palopegteriparatide: A long-acting prodrug version of PTH(1-34), sold as Yorvipath. Approved in 2024 for chronic hypoparathyroidism rather than osteoporosis, it slowly releases active PTH over about 60 hours, mimicking the body’s own steady hormone output rather than producing the sharp peaks used to build bone.⁴

The distinction between the first two and the third matters. Teriparatide and abaloparatide are designed to produce a brief daily spike, harnessing the anabolic window. Palopegteriparatide is designed to produce something closer to what healthy parathyroid glands do all day: a steady, low-level release that keeps calcium in range.

Treating Osteoporosis

Teriparatide was a breakthrough for people with severe osteoporosis who were still fracturing on older drugs like bisphosphonates. In its pivotal trial, the 20-microgram daily dose reduced new spinal fractures by about 65% and non-spinal fragility fractures by about 54% compared with placebo over roughly 19 months.⁵ A later meta-analysis of randomized trials broadly confirmed these numbers, finding about a 70% reduction in vertebral fractures and a 38% reduction in non-vertebral fractures.⁶ The bone density gains and fracture protection appear to persist for a time even after the drug is stopped, an important feature given that treatment courses are limited in duration.⁷

Abaloparatide has shown comparable or slightly better results in head-to-head comparisons. In the ACTIVE trial, new vertebral fractures occurred in under 1% of women on abaloparatide versus about 4% on placebo over 18 months. Teriparatide, included as an active comparator, landed between the two. For major osteoporotic fractures, abaloparatide outperformed placebo dramatically and showed a statistically meaningful advantage over teriparatide in a pre-specified analysis.⁸ A network meta-analysis pooling data across treatments ranked abaloparatide as having the highest probability of preventing vertebral, non-vertebral, and wrist fractures relative to other available therapies.⁹

A subgroup analysis of women at the highest fracture risk found similarly strong results: abaloparatide cut new vertebral fractures and major osteoporotic fractures substantially, with bone density gains at the spine, hip, and femoral neck at every time point measured.¹⁰

Glucocorticoid-Induced Osteoporosis

People taking long-term corticosteroids (prednisone, for example) face a special kind of bone loss driven partly by direct suppression of osteoblasts. Bisphosphonates help, but teriparatide appears to work better in this population. In a head-to-head trial against alendronate, teriparatide produced roughly twice the bone density gain at the spine (about 7% versus 3%) over 18 months and far fewer new vertebral fractures: under 1% with teriparatide versus about 6% with alendronate.¹¹ That makes intuitive sense: when the problem is that bone-building cells are being suppressed by steroids, a drug that directly stimulates those cells has an advantage over one that merely slows bone removal.¹²

Hypoparathyroidism

Hypoparathyroidism, usually the result of damage to or removal of the parathyroid glands during thyroid surgery, leaves patients unable to regulate calcium on their own. The traditional treatment is high doses of calcium supplements and active vitamin D, which keeps blood calcium in range but does nothing to restore normal phosphorus metabolism or protect the kidneys from excess calcium in the urine. PTH replacement offers a more physiologic fix.

Both teriparatide (given via injection or, experimentally, via pump) and the newer palopegteriparatide can normalize serum calcium while substantially reducing the need for calcium and active vitamin D supplements.¹³ The pump delivery of teriparatide has shown particular promise: compared with twice-daily injections, continuous pump delivery produced less calcium fluctuation, cut urine calcium by over half, and allowed a 65% dose reduction to maintain normal levels.¹⁴

Palopegteriparatide’s long half-life of about 60 hours makes pump delivery unnecessary. In its phase 2 trial, treatment allowed over 90% of participants to stop conventional therapy entirely and maintained normal blood calcium over 26 weeks.¹⁵ The FDA approved it in 2024 for this indication, and it also lowers urinary calcium and serum phosphate, addressing two complications that calcium-and-vitamin-D therapy alone does not handle well.¹⁶

Why Sequencing With Other Drugs Matters

Bone-building drugs like teriparatide and abaloparatide are typically used for a limited window, after which patients need to transition to an antiresorptive medication (like a bisphosphonate or denosumab) to preserve the gains. The order of this sequence matters a great deal. Starting with the anabolic agent and then following with the antiresorptive produces better outcomes than the reverse. If you give a bisphosphonate first and then switch to teriparatide, the anabolic response is blunted, and bone density gains are smaller.¹⁷ This is one of the field’s clearest practical lessons: if a patient qualifies for an anabolic agent, it’s better to use it first rather than saving it for later.¹⁸

Combination therapy, using an anabolic and an antiresorptive simultaneously, has also been studied. Two years of teriparatide plus denosumab increased spine bone density by about 13%, hip density by about 6%, and femoral neck density by about 7%, all exceeding what either drug achieved alone.¹⁹ A meta-analysis confirmed that the combination outperformed monotherapy at both the spine and hip without increasing side effects.²⁰ One trial explored doubling the standard teriparatide dose to 40 micrograms while combining it with denosumab, and saw spine density jump by roughly 17.5% in just 15 months, compared with about 9.5% on the standard dose combination.²¹ These are among the largest bone density increases reported with any drug regimen, though combination use is not yet standard practice for most patients.

Side Effects and Safety Concerns

The most common side effects of teriparatide and abaloparatide are mild: dizziness, nausea, leg cramps, and brief lightheadedness after injection. The more significant concern is hypercalcemia. PTH analogs raise calcium levels by design, and in some patients, especially those also taking calcium supplements, levels can climb too high. Elevated blood calcium and hypercalciuria are relatively common during teriparatide therapy, though they typically resolve quickly once the drug is stopped.²² In rare cases, persistent or severe hypercalcemia can require hospitalization and treatment with fluids and calcium-lowering agents.²³

The issue that hung over PTH analogs for nearly two decades was osteosarcoma, a rare and aggressive bone cancer. In preclinical studies, rats given high doses of teriparatide for most of their lifespans developed osteosarcoma. When the drug launched in 2002, it carried a boxed warning (the most serious type of FDA label alert), and treatment was limited to two years. Over the next 18 years, multiple real-world studies tracked teriparatide-treated patients and linked pharmacy claims data with cancer registries. None found an increase in osteosarcoma compared with untreated groups or the general population’s background rate of the disease.²⁴ Based on this accumulated evidence, the FDA removed the boxed warning and revised the two-year limitation in 2020.²⁵ The drug is still not recommended for people at elevated baseline risk for osteosarcoma (such as those with Paget’s disease, unexplained elevations in alkaline phosphatase, prior radiation to the skeleton, or open growth plates), but the blanket cancer worry that defined the drug’s early years no longer holds up.

Self-Injection and Adherence

All currently approved PTH analogs for osteoporosis require daily subcutaneous injection, which understandably gives patients pause. In a study of people who had already failed or couldn’t tolerate oral bisphosphonates, about 42% were initially concerned about injection discomfort. But after six months, over 90% reported much less concern or none at all, and reported compliance was 89% at six months and 82% at 18 months.²⁶ The injection uses a small, pre-filled pen device similar to what people with diabetes use, and the needle is fine enough that most patients adapt quickly. That said, 18% had dropped off by a year and a half, and real-world adherence outside clinical trials is almost certainly lower. Cost, inconvenience, and injection fatigue all play roles.

Using PTH Analogs for Fracture Healing

Outside of osteoporosis and hypoparathyroidism, clinicians have explored teriparatide for a problem it wasn’t specifically approved for: fractures that fail to heal. Delayed unions and nonunions, where a broken bone doesn’t knit together on its expected timeline, are frustrating for patients and often end up requiring surgery. A systematic review of case reports and small studies found that over 95% of patients with delayed or nonunion fractures treated with teriparatide eventually achieved complete healing, with no reported side effects during follow-up.²⁷ Another systematic review concluded that teriparatide appears to enhance fracture healing time, particularly for atypical femur fractures, which are themselves sometimes caused by long-term bisphosphonate use.²⁸

The evidence here is promising but thin. Most of it comes from case reports and small case series rather than large randomized trials, which makes it hard to know how much of the healing would have happened without the drug. Still, orthopedic surgeons do prescribe teriparatide off-label for stubborn nonunions, particularly when the patient is a poor surgical candidate or has underlying bone quality issues.²⁹

Kidney Disease Complicates the Picture

People with chronic kidney disease (CKD) develop bone problems through multiple overlapping pathways, and their calcium and phosphorus metabolism is already disrupted, which makes adding a PTH analog more complicated. Teriparatide is not well-studied in advanced CKD, and most of the pivotal osteoporosis trials excluded people with severely reduced kidney function. A Japanese post-hoc analysis of elderly women with stage 4 and 5 CKD found that teriparatide still appeared to improve bone density and bone formation markers, with no serious adverse reactions in a small group of 33 patients.³⁰ However, the risk of hypercalcemia appears to be considerably higher in CKD patients, with one estimate putting it at about 22%, driven by the already-abnormal calcium and phosphorus balance and parathyroid function in these individuals.³¹ For patients with advanced kidney disease, use of these drugs requires careful monitoring and close coordination between endocrinologists and nephrologists.

Cost and Access

PTH analogs are expensive. When health economists have compared the five main drugs used for very-high-risk postmenopausal osteoporosis in the United States, intravenous zoledronate (a bisphosphonate) is consistently the cheapest strategy. Teriparatide comes out the least cost-effective of the group, with an incremental cost-effectiveness ratio of roughly $477,000 per quality-adjusted life year gained over zoledronate. Abaloparatide fares better at about $176,000 per QALY, and romosozumab (a different anabolic mechanism) sits between the two at about $99,000.³² These numbers do not mean the drugs aren’t worthwhile for individual patients, particularly those who have already fractured on other therapies, but they explain why insurers often require prior authorization and documentation of bisphosphonate failure before covering PTH analogs.

Generic teriparatide has become available in some markets, which should ease price pressure over time. Abaloparatide remains under patent. Palopegteriparatide, as a newly approved orphan drug for a rare condition, will likely carry orphan-drug-level pricing for the foreseeable future. For patients, the practical upshot is that access depends heavily on insurance coverage, prior treatment history, and sometimes an appeal process.

Where the Field Is Headed

The removal of teriparatide’s boxed warning in 2020 quietly expanded the drug’s potential reach: clinicians are now less hesitant to prescribe it, and there is less concern about extending treatment beyond two years in patients who are benefiting. Palopegteriparatide’s approval for hypoparathyroidism filled a gap that had existed for decades; people who lost their parathyroid glands in surgery finally have a hormone replacement that mimics what their glands used to do, rather than just flooding them with calcium pills. Research into oral formulations, microneedle patches, and other needle-free delivery methods for PTH analogs is ongoing, though nothing beyond daily injections has reached the market for osteoporosis yet. The combination of teriparatide with denosumab continues to attract interest as a way to maximize bone density gains in the highest-risk patients, and longer-term fracture outcome data from those trials will clarify whether the impressive density increases actually translate into fewer broken bones over five or ten years.